Delving into the Latest Updates on Gallium-68 PSMA-617 with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals

Synonyms

+ [3]

Target

PSMA

Mechanism

PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Prostatic Cancer

Inactive Indication-

Originator Organization

Ruprecht-Karls-Universität Heidelberg

Active Organization

Peking Union Medical College Hospital

Ruprecht-Karls-Universität Heidelberg

German Cancer Research Center

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC49H66GaN9O16

InChIKeyPAXMZYRHVDZFFV-VSVMWJISSA-I

CAS Registry2247839-19-4

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging. This pilot study was prospectively designed to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PET/CT in patients with PCa

Start Date01 Jul 2021

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT04796467 / RecruitingPhase 2/3IIT

A Pilot Prospective Comparison of 68Ga-P16-093 and 68Ga-PSMA-617 in the Same Group of Prostate Cancer Patients

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the widely studied 68Ga-PSMA-617. This pilot study was prospectively designed to evaluate the early dynamic distribution of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-617 in the same group of prostate cancer patients.

Start Date01 Oct 2020

Sponsor / Collaborator

Peking Union Medical College Hospital

100 Clinical Results associated with Gallium-68 PSMA-617

Login to view more data

100 Translational Medicine associated with Gallium-68 PSMA-617

Login to view more data

100 Patents (Medical) associated with Gallium-68 PSMA-617

Login to view more data

15

Literatures (Medical) associated with Gallium-68 PSMA-617

01 Apr 2023·Clinical Nuclear Medicine

Head-to-Head Comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer

Article

Author: Hong, Haiyan ; Zang, Jie ; Kung, Hank F ; Wang, Guochang ; Zhu, Lin ; Zhu, Zhaohui ; Li, Linlin

PurposeWe aimed to compare the diagnostic performance of 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients.Patients and MethodsThirty untreated primary PCa patients were enrolled. Each patient underwent 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT within a week. In addition to visual analysis, SUV was measured for semiquantitative comparison and correlation analysis.Results68Ga-P16-093 PET/CT detected more positive tumors than 68Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). Further, 68Ga-P16-093 PET/CT exhibited significantly higher SUVmax of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). Besides, the SUVmax of high-risk patients (based on D’Amico classification) on 68Ga-P16-093 PET/CT was significantly higher than that of low- and intermediate-risk PCa patients (20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2, P = 0.007). The SUVmax of tumor measured by 68Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score (r = 0.462, P = 0.005) and prostate-specific antigen value (r = 0.491, P = 0.002), and significantly correlated with PSMA expression (r = 0.732, P < 0.001).Conclusions68Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68Ga-PSMA-617 PET/CT, which suggested that 68Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients.

01 Mar 2023·Journal of Nuclear Medicine

Comparison of⁶⁸Ga-PSMA-617 PET/CT and⁶⁸Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study

Article

Author: Schollhammer, Romain ; Gallerande, Henri de Clermont ; Balamoutoff, Nicolas ; Robert, Grégoire ; Bladou, Franck ; Vimont, Delphine ; Asselineau, Julien ; Bénard, Antoine ; Morgat, Clément ; Yacoub, Mokrane ; Hindié, Elif

Considering the wide range of therapeutic options for localized prostate cancer (e.g., active surveillance, radiation-beam therapy, focal therapy, and radical prostatectomy), accurate assessment of the aggressiveness and localization of primary prostate cancer lesions is essential for treatment decision making. National Comprehensive Cancer Network guidelines recognize prostate-specific membrane antigen (PSMA) PET/CT for use in initial staging of high-risk primary prostate cancer. The gastrin-releasing peptide receptor (GRP-R) is a neuropeptide receptor overexpressed by low-risk prostate cancer cells. We aimed to perform the first (to our knowledge) prospective head-to-head comparison of PSMA- and GRP-R-targeted imaging at initial staging to understand how PSMA PET and GRP-R PET can be used or combined in clinical practice. Methods: This was a prospective, single-center, diagnostic cross-sectional imaging study using anonymized, masked, and independent interpretations of paired PET/CT studies in 22 patients with ⁶⁸Ga-PSMA-617 (a radiolabeled PSMA inhibitor) and ⁶⁸Ga-RM2 (⁶⁸Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2, a radiolabeled GRP-R antagonist). We enrolled patients with newly diagnosed, biopsy-proven prostate cancer. None had received neoadjuvant hormone therapy or chemotherapy, and all underwent extended pelvic lymph node dissection. Histologic findings served as a reference. Results: On a lesion-based analysis (including lesions < 0.1 cm³), ⁶⁸Ga-PSMA-617 PET/CT detected 74.3% (26/35) of all tumor lesions and ⁶⁸Ga-RM2 PET/CT detected 78.1% (25/32; 1 patient could not be offered ⁶⁸Ga-RM2 PET/CT). Paired examinations showed positive uptake of the 2 tracers in 21 of 32 lesions (65.6%), negative uptake in 5 of 32 lesions (15.6%), and discordant uptake in 6 of 32 lesions (18.8%). Uptake of ⁶⁸Ga-PSMA-617 was higher when the International Society of Urological Pathology (ISUP) score was at least 4 versus at least 1 (P < 0.0001) or 2 (P = 0.0002). There were no significant differences in uptake between ISUP scores for ⁶⁸Ga-RM2. Median ⁶⁸Ga-RM2 SUV_max was significantly higher than median ⁶⁸Ga-PSMA-617 SUV_max in the ISUP-2 subgroup (P = 0.01). Conclusion: ⁶⁸Ga-PSMA-617 PET/CT is useful to depict higher, more clinically significant ISUP score lesions, and ⁶⁸Ga-RM2 PET/CT has a higher detection rate for low-ISUP tumors. Combining PSMA PET and GRP-R PET allows for better classification of intraprostatic lesions.

01 Oct 2021·Nuclear Medicine and Molecular Imaging

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

Article

Author: Ghorbani, Mahdi ; Pirayesh, Elahe ; Amoui, Mahasti ; Rad, Mehrdad Ghorbani ; Mahmoudi, Elahe ; Deevband, Mohammad Reza

PURPOSE¹⁷⁷Lu-DKFZ-PSMA-617 is a promising treatment for patients with metastatic prostate cancer. Specific dosimetry for each patient is an important factor in planning the patient's treatment process. This study aimed to perform an image-based absorbed dose calculation for the treatment of metastatic prostate cancer with ¹⁷⁷Lu-DKFZ-PSMA-617.METHODSThe individualized patient dosimetry calculations were based on whole-body planar scintigraphy images acquired in 10 patients with a mean age of 71.4 ± 6.07 years (range 63-85 years) at approximately 0-2 h, 4-6 h, 18-24 h, and 36-48 h after administration of the mean 6253 ± 826.4 MBq (range 5500-7400 MBq) of ¹⁷⁷Lu-DKFZ-PSMA-617. Time-activity curves were generated for various organs. For count conversion to activities, calibration factors were calculated. Finally, the absorbed dose for an individual cycle was calculated using IDIAC-DOSE 2.1 software.RESULTSOn average, the calculated absorbed dose for the kidneys and salivary glands were 0.46 ± 0.09 mGy/MBq and 0.62 ± 0.07 mGy/MBq, respectively.CONCLUSIONSBased on the results, the¹⁷⁷Lu-PSMA-617 therapy is a safe method for the treatment of castration-resistant prostate cancer patients. Large inter-individual variations in organ dose were found, demonstrating the need for patient-specific dosimetry and treatment planning.

100 Deals associated with Gallium-68 PSMA-617

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Prostatic Cancer	Phase 3	CN	Peking Union Medical College Hospital	01 Oct 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2020	Not Applicable	-	-	68Ga-PSMA-617	aalmltiuao(ubalubkppv) = kpjkwxvunz dvhhxwctld (xyvnqmauwx ) View more	-	15 May 2020
SNMMI2020	Not Applicable	-	-	68 Ga-PSMA-61768Ga-PSMA-617 (Cyclotron-produced 68Ga-PSMA-617)	prcnoutvlf(qyueztqusw) = >95% zmjmpajqim (egiurarjth ) View more	-	15 May 2020